Back to results list
Show full item record
Please use this identifier to cite or link to this item:
|Title:||Effect of ceftiofur and enrofloxacin on E-coli sub-population in pig gastrointestinal tract||Authors:||Lin, DC
|Issue Date:||2017||Publisher:||Elsevier||Source:||Journal of global antimicrobial resistance, 2017, v. 10, p. 126-130 How to cite?||Journal:||Journal of global antimicrobial resistance||Abstract:||Background: Antibiotic resistant sub-population of the gut microbiome in both human and animals may be enriched during antimicrobial treatment. Methods: This study investigated how the size and antibiotic susceptibility profiles of antibiotic resistant sub-population organisms in the animal gastrointestinal tract changed upon exposure to different levels of ceftiofur and enrofloxacin by plating fecal samples collected from piglets before and after antibiotic treatment onto MacConkey agar containing 0.5 mu g/ml cefotaxime and determination of the resistance rate. Genetic characteristics and relatedness of strains collected before and after treatment was tested to determine if resistant Escherichia coli strains that emerged after treatment was due to dissemination of resistance-encoding mobile elements or clonal expansion of specific strains. Results: Antibiotic resistant organisms constituted a varied but significant proportion of the gut flora regardless of the degree of previous exposure to antibiotics; the proportion of sub-population resistant organisms in the gut flora decreased but remained detectable even 10 days after antibiotic selection pressure had been relieved, and increased again upon renewed exposure to antibiotic regardless of the approach of administration. The increased prevalence of cefotaxime resistant strains in the animal GI tract upon treatment with sub-therapeutic and therapeutic concentrations of ceftiofur/enrofloxacin was respectively attributed to transmission of bla(CTX-M)-borne plasmids and clonal expansion of pre-existing resistant strains. Conclusion: The gut flora of animals comprises a high baseline level of resistance, among which resistant organisms cannot be eradicated but instead being further enriched in successive episodes of antibiotic treatment.||URI:||http://hdl.handle.net/10397/75931||ISSN:||2213-7165||EISSN:||2213-7173||DOI:||10.1016/j.jgar.2017.05.010|
|Appears in Collections:||Journal/Magazine Article|
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.